1,627 matches
-
RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259. 5. du Bois A, Luck H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. JNCI Cancer Spectrum 2003; 95: 1320-1329. 6. Fader AN, Rose PG. Role of surgery în ovarian carcinoma. J Clin Oncol 2007; 25:2873-2883. 7. Goonewardene TI, Hall MR
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8. 9. ICON Collaborators. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin în women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-515. 10. Kavanagh JJ, Pecorelli S, Benedet JL et al. Cancer of the ovary. În Pecorelli S, Ngan HYS, Hacker NF (eds): Staging Classifications and Clinical Practice.Guidelines for Gynaecological Cancers, 3rd edition. International Federation of Gynecology
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
docs/ staging booklet.pdf. 11. Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse în advanced ovarian cancer. J Clin Oncol 2006; 24: 1454-1458. 12. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel în patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465. 13. McGuire WP
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel în patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465. 13. McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin în patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin în patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6. 14. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel în patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200. 15. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200. 15. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin în patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J ClinOncol 2006; 24: 4699-4707. 16. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide în women with advanced epithelial ovarian cancer: three-year results
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
carboplatin compared with carboplatin în patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J ClinOncol 2006; 24: 4699-4707. 16. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide în women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708. 17. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
92: 699-708. 17. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497. 18. Rustin GJ, Bast RC, Jr., Kelloff GJ et al. Use of CA-125 în clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926. 19. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551. 20. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy în Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy ��n patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112. 21. van der Burg ME, van Lent M, Buyse M
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551. 20. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy în Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy ��n patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112. 21. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
3-6 cicluri este recomandat pentru chimioterapia adjuvantă postoperatorie și la pacienții cu TSCS recurente. Taxanii au demonstrat o activitate interesantă în TSCS cu un profil de toxicitate favorabil [III, A]. Combinațiile între taxani și platină constituie un candidat rațional pentru trialurile viitoare. Există puține dovezi pentru utilizarea hormonoterapiei și a radioterapiei și aceste modalități vor fi restrânse la cazuri selectate. Evaluarea răspunsului Markerii tumorali serici (hCG, AFP, LDH, CA 125 și inhibina) pot fi corelați cu acuratețe cu răspunsul tumoral în
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52: 50-55. 12. Gershenson DM. Management of early ovarian cancer: germ cell and sex-cord stromal tumors. Gynecol Oncol 1994; 55: S62-S72. 13. Bajorin DF, Sarosdy MF, Pfister GD et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin în patients with good-risk germ cell tumors: a mulți-instituțional study. J Clin Oncol 1993; 11: 598-606. 14. Homesley HD, Bundy BN, Hurteau JA et al. Bleomycin, etoposide, and cisplatin combination therapy of
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
carcinomas: a critical parameter în treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-1056. 13. Keys HM, Bundy TM, Stehman FB et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003; 89: 343-353. 14. Timotheadou E, Gore ME. Neoadjuvant chemotherapy for locally advanced cervical cancer. Eur J Cancer 2003; 39: 2419-2421. 15. Tzioras S, Pavlidis N, Paraskevaidis E et al. Effects of different
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000; 182: 1506-1519. 6. Scholten AN, van Putten WLJ, Beerman H et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiation Oncology Biol Phys 2005; 63: 834-838. 7. Lukka H, Chambers A, Fyles A et al. Adjuvant radiotherapy în women with stage I endometrial cancer: a systematic review. Gynecol Oncol 2006; 102: 361-368. 8
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
G et al. Doxorubicin versus doxorubicin and cisplatin în endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448. 12. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim în advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159-2166. 13. Randall ME, Brunetto G, Muss HB et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
filgastrim în advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159-2166. 13. Randall ME, Brunetto G, Muss HB et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy în advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. J Clin Oncol 2006; 24: 36-44. Cancerul esofagian Recomandările ESMO pentru diagnosticare, tratament și urmărire M. Stahl*1) amp; J. Oliveira*2) Din partea Grupului de Lucru ESMO pentru Ghiduri Terapeutice*) *1) Department of Medical Oncology
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2005; 16: 481-488. 2. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507. 3. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174. 4. Fiorca F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
92: 1976-1983. 8. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy în esophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234. 9. Bedenne L, Michel P, Bouche O et al. Randomized phase III trial în locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002; 21: 130a (Abstr 519). Cancerul gastric Recomandările ESMO pentru diagnosticare, tratament și monitorizare C. Jackson*1), D. Cunningham*1) amp
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Ann Oncol 2007; 18: 581-592. 2. Meluch AA, Greco FA, Gray JR et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy în locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003; 9: 251-260. 3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. 4. Boige V, Pignon J, Saint-Aubert B et al. Final
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
251-260. 3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. 4. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone în adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (Meeting Abstracts) 2007; 25: 4510. 5. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
J Med 2006; 355: 11-20. 4. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone în adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (Meeting Abstracts) 2007; 25: 4510. 5. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730. 6
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Ann Oncol 2008; 19: 1450-1457. 12. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46. 13. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy în patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts) 2006; 24: LBA4018. 14. Al-Batran S-E, Hartmann JT
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
infusion of 5-FU/cisplatin (FP) as first-line therapy în patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts) 2006; 24: LBA4018. 14. Al-Batran S-E, Hartmann JT, Probst S et al. Phase III trial în metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442. 15. Okines AFC NA, McCloud P, Kang Y-K, Cunningham D. Meta-analysis of the REAL-2 and
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
N Am 1998; 7: 67-91. 3. IchiKawa T, Haradome H. Hachiya et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997; 202: 655-662. 4. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210. 5. Oettle H, Post S, Neuhaus P, Gellert K et al. Adjuvant chemotherapy with gemcitabine vs observation în patients undergoing curative-intent resection of pancreatic
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210. 5. Oettle H, Post S, Neuhaus P, Gellert K et al. Adjuvant chemotherapy with gemcitabine vs observation în patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277. 6. Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381. 7. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy
EUR-Lex () [Corola-website/Law/227406_a_228735]